The Division of Experimental Medicine and Immunotherapeutics (EMIT) was established in 2014 from the Division of Clinical Pharmacology and the Vasculitis section of the Department of Medicine, Addenbrooke’s Hospital. Our raison d’etre is the translation of benchside science into human clinical research. We conduct our work primarily in the purpose-built clinical and basic science laboratories in the Addenbrooke’s Centre for Clinical Investigation, funded by the BHF and on Level 5, Department of Medicine.
Research in this cross-cutting themed Division primarily concerns studies in healthy volunteers to dissect normal physiology and understand pharmacology of new molecules, and trials in patients including interventional clinical trials, end-point and outcome measure development and biomarker validation. The division is developing an active programme to support career development in experimental medicine.
Our Research
Research within the Experimental Medicine and Immunotherapeutics (EMIT) Division is broad in nature. Our main focus is on translating basic scientific findings broadly within the fields of hypertension and cardiovascular medicine into clinical applications (generally drugs). In addition we are at the forefront of clinical trial research here in Cambridge.
Education and Training
The Experimental Medicine and Immunotherapeutics (EMIT) Division generates leading clinicians and research scientists through a number of courses and programmes. We also actively encourage up and coming scientists, providing internship opportunities for undergraduate students.
